Robert G. Bachner

Array ( [id] => 19281780 [patent_doc_number] => 20240218254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME [patent_app_type] => utility [patent_app_number] => 18/286274 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233633 [patent_doc_number] => 20240190825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => PROCESS FOR PREPARATION OF CABOZANTINIB [patent_app_type] => utility [patent_app_number] => 18/283281 [patent_app_country] => US [patent_app_date] => 2022-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217757 [patent_doc_number] => 20240182461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS [patent_app_type] => utility [patent_app_number] => 18/283489 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971822 [patent_doc_number] => 20240051914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => THE HEXADECANE TROMETHAMINE COMPOUND, ITS SYNTHESIS METHOD AND ITS APPLICATION IN ANTITUMOR AND ANTIFUNGAL ASPECTS [patent_app_type] => utility [patent_app_number] => 17/998119 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20437449 [patent_doc_number] => 12508270 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Treatment of behavioral impairment in developmental and epileptic encephalopathy [patent_app_type] => utility [patent_app_number] => 17/697629 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4462 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217771 [patent_doc_number] => 20240182475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION [patent_app_type] => utility [patent_app_number] => 18/282426 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670880 [patent_doc_number] => 20220184047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/685892 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17685892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685724 [patent_doc_number] => 20220193016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => COMPOSITIONS, METHODS AND USES FOR TARGETING C-TERMINAL BINDING PROTEIN (CtBP) IN TRAUMATIC BRAIN INJURY [patent_app_type] => utility [patent_app_number] => 17/686128 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111189 [patent_doc_number] => 20240122939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF CDKL5 GENE [patent_app_type] => utility [patent_app_number] => 18/273491 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329685 [patent_doc_number] => 12459950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) [patent_app_type] => utility [patent_app_number] => 17/674010 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48565 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156048 [patent_doc_number] => 20240148755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => WATER-BASED PHARMACEUTICAL COMPOSITION CONTAINING URSODEOXYCHOLIC ACID OR SALT THEREOF [patent_app_type] => utility [patent_app_number] => 18/546135 [patent_app_country] => US [patent_app_date] => 2022-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18160665 [patent_doc_number] => 20230027257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE [patent_app_type] => utility [patent_app_number] => 17/671436 [patent_app_country] => US [patent_app_date] => 2022-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17671436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556389 [patent_doc_number] => 20240368181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => QUINOXALINE DERIVATIVES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/275232 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 120518 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865314 [patent_doc_number] => 20220288049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => BIOACTIVE PHYTOCHEMICALS [patent_app_type] => utility [patent_app_number] => 17/584744 [patent_app_country] => US [patent_app_date] => 2022-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17584744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329651 [patent_doc_number] => 12459916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals [patent_app_type] => utility [patent_app_number] => 17/570550 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 14 [patent_no_of_words] => 23010 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19682279 [patent_doc_number] => 20250000824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/532209 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548051 [patent_doc_number] => 20220119392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/566376 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17566376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986357 [patent_doc_number] => 20240058326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => METHODS OF TREATING MENTAL OR MOOD DISORDERS USING 2-BROMO-LSD [patent_app_type] => utility [patent_app_number] => 18/269080 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081789 [patent_doc_number] => 20240108590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => MAINTENANCE OF PROGRAMMED CHRONIC LIVER INJURY OF FAH GENE-DEFICIENT ANIMALS AND APPLICATION THEREOF IN PREPARATION OF HETEROLOGOUS LIVER MODELS [patent_app_type] => utility [patent_app_number] => 18/039105 [patent_app_country] => US [patent_app_date] => 2021-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432404 [patent_doc_number] => 20240300902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => NOVEL TRANSGLUTAMINASE 2 INHIBITOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/913296 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17913296 [rel_patent_id] =>[rel_patent_doc_number] =>)